The FDA drugs database lists a supplemental approval dated 20 August 2026 for ZELBORAF, vemurafenib, under Hoffmann-La Roche's application NDA 202429.
The record does not say what the supplement covers. Supplements commonly update labelling, manufacturing or presentation, and nothing in the record indicates a new indication or a new safety warning.
Vemurafenib's indications for BRAF V600-mutated disease are unchanged on current information. Its status with CDSCO is not affected by this US action.
- No change to vemurafenib indications follows from this record
- Check the updated FDA label if you prescribe vemurafenib
- Continue skin surveillance for new primary cancers and ECG monitoring for QT prolongation
Why it matters
Supplements are routine, and reading one as a new indication would be an error.
Don't overread it
A licence supplement is not a new indication or safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free